Breadcrumbs

Upper gastrointestinal - oncology

Gastric and oesophageal

Protocol Administration at chemotherapy unit level Review date
Gastric adjuvant CAPOX (XELOX) (capecitabine and oxaliplatin) Medium September 2022
Gastric and gastroesophageal metastatic cISplatin capecitabine trastuzumab Medium. Moves to low risk after completion of cISplatin/capecitabine treatment March 2020
Gastric and gastroesophageal metastatic cISplatin fluorouracil trastuzumab Medium. Moves to low risk after completion of cISplatin/fluorouracil treatment September 2020
Gastric and oesophageal metastatic cISplatin capecitabine Medium March 2021
Gastric and oesophageal metastatic cISplatin fluorouracil Medium 2 September 2022
Gastric and gastroesophageal metastatic DOCEtaxel Medium March 2020
Gastric and gastroesophageal metastatic FOLFIRI (modified) (fluorouracil leucovorin irinotecan) Medium September 2020
Gastric and gastroesophageal metastatic FOLFOX6 (modified) (fluorouracil leucovorin oxaliplatin) Medium March 2021
Gastric and gastroesophageal metastatic irinotecan (two weekly) Medium September 2022
Gastric and gastroesophageal metastatic PACLitaxel (weekly) Medium March 2020
Gastric and gastroesophageal neoadjuvant and adjuvant FLOT (fluorouracil leucovorin oxaliplatin and DOCEtaxel) Medium September 2022
Oesophageal definitive cISplatin and fluorouracil chemoradiation followed by cISplatin and fluorouracil Medium 2,3 March 2021
Oesophageal definitive FOLFOX6 (modified) (fluorouracil leucovorin oxaliplatin) chemoradiation Medium September 2022
Oesophageal neoadjuvant cARBOplatin and PACLItaxel weekly chemoradiation pre-operative Medium 3 March 2020
Oesophageal neoadjuvant cISplatin and fluorouracil chemoradiation Medium 2,3 September 2020

Gastrointestinal stromalcell tumours

Protocol Administration at chemotherapy unit level Review date
Gastrointestinal stromal cell tumour (GIST) adjuvant imatinib Low March 2021
Gastrointestinal stromal cell tumour (GIST) metastatic imatinib Low September 2022
Gastrointestinal stromal cell tumour (GIST) metastatic regorafenib Low March 2020
Gastrointestinal stromal cell tumour (GIST) metastatic sunitinib Low September 2020

Hepatic

Protocol Administration at chemotherapy unit level Review date
Hepatic advanced or metastatic lenvatinib
Low September 2022
Hepatic advanced sorafenib Low March 2021

Neuroendocrine

Protocol Administration at chemotherapy unit level Review date
Neuroendocrine advanced cARBOplatin etoposide Medium September 2022
Neuroendocrine advanced cISplatin and etoposide Medium March 2020
Neuroendocrine advanced lanreotide (somatuline autogel) Low September 2020
Neuroendocrine advanced octreotide (sandostatin LAR) Low March 2021
Neuroendocrine pancreatic advanced everolimus Low September 2022
Neuroendocrine pancreatic advanced sunitinib Low March 2020
Neuroendocrine advanced capecitabine and temozolomide Medium September 2020

Pancreas and biliary

Protocol Administration at chemotherapy unit level Review date
Biliary and gallbladder metastatic cARBOplatin and gemcitabine

Medium Day 1 Low Day 8

March 2021
Biliary and gallbladder metastatic cISplatin and gemcitabine Medium September 2022
Biliary and gallbladder metastatic gemcitabine Low March 2020
Biliary tract cancer adjuvant capecitabine Low June 2022
Pancreas adjuvant capecitabine and gemcitabine Medium September 2020
Pancreas adjuvant FOLFIRINOX (modified) (fluorouracil leucovorin irinotecan oxaliplatin)
Medium September 2022
Pancreas adjuvant gemcitabine Low March 2021
Pancreas advanced gemcitabine Medium September 2022
Pancreas capecitabine chemoradiation Low 3 March 2020
Pancreas fluorouracil chemoradiation Low 3 September 2020
Pancreas metastatic FOLFIRI (modified) (fluorouracil leucovorin irinotecan) Medium March 2021
Pancreas metastatic FOLFIRINOX (modified) (fluorouracil leucovorin irinotecan oxaliplatin) Medium March 2021
Pancreas metastatic gemcitabine and nab-PACLItaxel Medium September 2020
Pancreas metastatic irinotecan nanoliposomal, fluorouracil and leucovorin Medium September 2021
Pancreas metastatic OFF (oxaliplatin fluorouracil leucovorin)
Medium September 2021

  1. Permitted to be administered in low-risk units for second and subsequent cycles for patients with ECOG performance status 0 or 1 showing ≤ Grade 1 toxicity
  2. Fluorouracil pumps may be connected/disconnected at low-risk units
  3. Local radiotherapy services required
  4. Non-formulary drug included in the protocol
  5. Continuation dual treatment with pertuzumab and trastuzumab can be provided to appropriate patients at low-risk chemotherapy units.

^ Back to top